Introduction: Atrial fibrillation (AF) complicates Bruton tyrosine kinase inhibitor therapy in chronic lymphocytic leukemia. Methods: We retrospectively evaluated 679 zanubrutinib-treated patients across 52 Italian centers, with 354 historical ibrutinib-treated controls. Shanafelt AF scores were assessed. Results: Nine zanubrutinib-treated patients developed AF (1.33%) during median treatment of 15.5 months, versus 42 historical controls (11.9%) over median observation of 25 months. Five zanubrutinib events occurred among patients scoring ≥ 5. No affected patients experienced embolic or bleeding complications. Conclusion: AF was uncommon during zanubrutinib treatment, even in the higher-risk subgroup. Historical comparisons remain limited, and exploratory score findings require confirmation with longer follow-up. Trial registration: The authors have confirmed clinical trial registration is not needed for this submission.
Atrial Fibrillation During Zanubrutinib Treatment in Chronic Lymphocytic Leukemia With a Historical Ibrutinib Control
Innao, Vanessa;Allegra, Alessandro;Fabro, Vittorio Del;Stagno, Fabio;
2026-01-01
Abstract
Introduction: Atrial fibrillation (AF) complicates Bruton tyrosine kinase inhibitor therapy in chronic lymphocytic leukemia. Methods: We retrospectively evaluated 679 zanubrutinib-treated patients across 52 Italian centers, with 354 historical ibrutinib-treated controls. Shanafelt AF scores were assessed. Results: Nine zanubrutinib-treated patients developed AF (1.33%) during median treatment of 15.5 months, versus 42 historical controls (11.9%) over median observation of 25 months. Five zanubrutinib events occurred among patients scoring ≥ 5. No affected patients experienced embolic or bleeding complications. Conclusion: AF was uncommon during zanubrutinib treatment, even in the higher-risk subgroup. Historical comparisons remain limited, and exploratory score findings require confirmation with longer follow-up. Trial registration: The authors have confirmed clinical trial registration is not needed for this submission.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.


